- Oops!Something went wrong.Please try again later.
DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement/9 Month figures
APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 - Revenue forecast increased
In the nine-month period 2021, APONTIS PHARMA continued to grow significantly faster than the overall market of the pharmaceutical industry and than the prescription drugs which are significant for the Company. A revenue increase of 37% to EUR 36.7 million underlines the dynamic business development. Single Pills revenues, exceeding expectations, were the main growth driver with a significant increase of 80% to EUR 21.8 million. The share of Single Pills in total revenues increased to around 60% (9M 2020: 45%). Only pandemic-related restrictions on market access in cooperation agreements for the co-promotion of patented products held back even stronger growth. The cost of materials and personnel expenses grew at a significantly slower rate than the revenue volume. Here, APONTIS PHARMA benefited in particular from its market-leading sales force in Germany and was as such able to compensate to a large extent for the reduced access to medical care for chronically ill patients as a result of the pandemic.
In order to systematically leverage the opportunities arising from the growth momentum of Single Pills for a higher earnings contribution in the coming year 2022, APONTIS PHARMA invested an additional EUR 0.2 million in marketing. Earnings before interest, taxes, depreciation and amortization (EBITDA adjusted), mainly adjusted for IPO costs, improved in the nine-month period 2021 to EUR 4.4 million (9M 2020: negative) with a plus of EUR 5.7 million due to the strong earnings contribution of Single Pills at group level.
The increase in current assets reflects an additional inventory build-up of EUR 0.8 million in preparation for the further increase in demand. With an equity ratio of around 76% and cash and cash equivalents of EUR 30.1 million and liabilities of EUR 4.9 million, APONTIS PHARMA boasts a solid asset and financial position as the basis for its planned growth.
For the 2021 financial year, the Executive Board is increasing its revenues forecast to up to EUR 49.5 million (previously EUR 48.5 million) and is confirming the forecast of EUR 5.5 million for adjusted EBITDA.
Note: The figures for 9M 2021 are unaudited. Rounding differences may occur.
CEO Karlheinz Gast and CPO Thomas Milz will explain the results of the nine-month period 2021 in a webcast presentation today, 18 November 2021, at 09.00 CET. The presentation will be held in English.
Please register in time to participate at:
The accompanying presentation will also be available on the Company's website prior to the start.
Condensed consolidated balance sheet (unaudited)
Condensed consolidated cash flow statement (unaudited)
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the Company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.
APONTIS PHARMA AG
APONTIS PHARMA Press Contact
CROSS ALLIANCE communication GmbH
18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
APONTIS PHARMA AG
Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID:
End of News
DGAP News Service